MMW Fortschritte der Medizin · 2010
[Efficacy and tolerability of pantoprazole in the treatment of gastroesophageal reflux disease].
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gillessen A
Аннотация
BACKGROUND: Proton pump inhibitors (PPI) are considered first-line therapies in the treatment of gastroesophageal reflux disease (GERD) and are prescribed frequently.
METHODS: In two non-interventional trials 3040 patients with GERD were treated with 20 mg/40 mg pantoprazole per day. Symptoms were assessed by the investigators as well as the patients by means of the symptom questionnaire ReQuest at study start and after 1 week of treatment with pantoprazole. Data were pooled and analysed.
RESULTS: At study start, 80% of patients had moderate/severe heartburn, 65% acid regurgitation, 20% painful swallowing and 32% suffered from moderate/severe steep dysfunction. After 1 week of treatment only 3.6% reported moderate/severe heartburn, 2.8% acid regurgitation, and 1.0% painful swallowing. Only 3.6% still suffered from sleep dysfunction. Improvement of symptoms was already observed after 1 to 2 days.
CONCLUSION: Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life.
METHODS: In two non-interventional trials 3040 patients with GERD were treated with 20 mg/40 mg pantoprazole per day. Symptoms were assessed by the investigators as well as the patients by means of the symptom questionnaire ReQuest at study start and after 1 week of treatment with pantoprazole. Data were pooled and analysed.
RESULTS: At study start, 80% of patients had moderate/severe heartburn, 65% acid regurgitation, 20% painful swallowing and 32% suffered from moderate/severe steep dysfunction. After 1 week of treatment only 3.6% reported moderate/severe heartburn, 2.8% acid regurgitation, and 1.0% painful swallowing. Only 3.6% still suffered from sleep dysfunction. Improvement of symptoms was already observed after 1 to 2 days.
CONCLUSION: Treatment with pantoprazole not only reliefs typical daily core symptoms but also improves the hitherto hardly noted sleep dysfunction and can, hence, bring a recovery of quality of life.
Предметные рубрики MeSH
2-PyridinylmethylsulfinylbenzimidazolesAdolescentAdultAgedAged, 80 and overAnti-Ulcer AgentsClinical Trials as TopicDose-Response Relationship, DrugEsophagitis, PepticFemaleGastroesophageal RefluxHumansMaleMiddle AgedMulticenter Studies as TopicPantoprazolePatient SatisfactionProspective StudiesQuality of LifeYoung Adult